Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

Dr. Sondhi is Research Professor in the Department of Genetic Medicine at Weill Cornell Medical College.

The focus of her research is:

Gene Therapy for Batten disease (Late Infantile and Juvenile forms)

Gene Therapy approaches for Alzheimer's disease

Gene Therapy for Metachromatic Leukodystrophy

Gene Therapy for Mucopolysaccahridosis I (Hurler Syndrome)

Gene Therapy for Rett Syndrome

Gene therapy for alpha-1 antitrypsin deficiency

Gene therapy for diffuse coronary artery disease

Vaccines for addictive drugs such as cocaine

Gene therapy for Glioblastoma

Gene Therapy for Friedreich's Ataxia

Highlights

  1. 1
    Science translational medicine · 2020
    DSDolan SondhiSMStephen M. KaminskyNRNeil R. HackettOPOdelya Pagovich+11 more →RGRonald G Crystal
    PMID: 33268510PMCID: PMC8056991DOIFirst author71 citations
  2. 2
    Human gene therapy · 2023
    SMStephen M. KaminskyRJRodolfo J Ricart ArbonaHRHeather Rose MartinRGRonald G CrystalDSDolan Sondhi
    PMID: 37166361PMCID: PMC10354731DOISenior author18 citations
  3. 3
    Human gene therapy · 2021
    JPJonathan P DykeDJDouglas J BallonRJRodolfo J Ricart ArbonaSMStephen M. Kaminsky+1 more →DSDolan Sondhi
    PMID: 33380277PMCID: PMC8236561DOISenior author32 citations

Publications

77 publications

Funding

14 grantsView NIH portfolio on RePORTER ↗

Active

4 grants
  • Co-I
    Gene Therapy for Alpha 1-Antitrypsin Deficiency
    National Heart, Lung, and Blood Institute · 2024–2028
    R61HL169190-01A1
  • Co-I
    Gene Therapy for APOE4 Homozygous Alzheimer's Disease
    National Institute on Aging · 2026–2028
    UG3AG098024-01
  • Co-I
    Lexeo Biopharma Agreement
    LEXEO Therapeutics, Inc. · 2025–2027BioPharma Alliance
    BP 251293-02
  • MPI
    MSA between Weill Cornell and FormBio
    Form Bio INC · 2025–2026Contract
    SA 251940-01
Completed grants (10)
  • Co-I
    Rapid Noninvasive Whole-body Imaging of AAV Gene Transfer Vectors
    National Institute of Biomedical Imaging and Bioengineering · 2019–2025
    R01EB027918-03
  • PI
    Comparison of Brain Biodistribution of Two CDKL5 Gene Therapy Vector Leads
    Orphan Disease Center at University of Pennsylvania · 2021–2022
    No publications yet
    ODCUP 214052-01
  • Co-I
    Gene Therapy for Chronic Traumatic Encephalopathy
    Daedalus Fund for Innovation (Weill Cornell) · 2019–2021BioPharma Alliance
    DFI 200106-01
  • Co-I
    LDN: Biomarkers for Disease Severity and Therapeutic Response in LINCL
    National Institute of Neurological Disorders and Stroke · 2009–2019 · via University of Minnesota· 2 renewals
    U54NS065768-10
  • PI
    AAVrh.10-mediated Npc2 Gene Transfer for the Treatment of Npc2 Deficient Niemann-Pick Disease
    University of Pennsylvania · 2018–2018
    MDBR-18-123-NPC
  • KP
    Disrupted Adenovirus Serotype 5-Based Anti-Cocaine Vaccine
    National Institute on Drug Abuse · 2012–2018
    U01DA033835-03
  • KP
    Intra-Arterial Gene Therapy for LINCL
    National Institute of Neurological Disorders and Stroke · 2015–2018
    R56NS082655-01A1
  • KP
    Final Preclinical Development of Gene Therapy for Post-Operative Atrial Fibrillation
    National Institute on Aging · 2014–2017 · via University of Massachusetts Medical Center
    R21AG042701-02 EW
  • KP
    Gene Therapy for Batten Disease Using AAVrh.10 Expressing Human CLN2 cDNA
    National Institute of Neurological Disorders and Stroke · 2010–2016
    R01NS061848-04EWO
  • PI
    Assessment of Three Routes of Delivery of the IDUA Gene (Gene Implicated in MPS-I) in Non-Human Primates Comparing Two Serotypes, AAV9 and AAVrh.10 for the Treatment of MPS-I
    Pennsylvania State University · 2013–2015
    MPSI-13-002-01EWOF

External relationships

Leadership Roles

Passage Bio, Inc.

Ownership

LEXEO Therapeutics, Inc. · Passage Bio, Inc.

Advisory/Scientific Board Member

Form Bio INC

Proprietary Interest

LEXEO Therapeutics, Inc.

Other

Gerson Lehrman Group (GLG) · Guidepoint Global LLC · Pacira Pharmaceuticals, Inc.